Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Layla vs Mevo Health

Layla
Graded #101

Higher grade

vs+10.700000000000003
Mevo Health
Graded #326

Lower grade

The verdict

Layla takes it — 70.9/100 to 60.2/100.

Layla grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Layla is a US telehealth weight-loss program built around semaglutide, offering compounded semaglutide as injections and as oral dropper drops, plus compounded tirzepatide and a brand-inclusive GLP-1…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueLayla +10
66
56
Dose & formulationLayla +13
96
83
Clinical oversightLayla +9
76
67
Labs & monitoringEven
52
52
FulfillmentLayla +8
65
57
Contract termsLayla +35
55
20
Layla · left barMevo Health · right bar

The numbers

MetricLaylaMevo Health
WeighScore70.9/10060.2/100
GradeCC
Scorecard rank#101#326
Semaglutide$237/mo (all doses, compounded)$199/mo (all doses, compounded)
Tirzepatide$199/mo (all doses, compounded)$259/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
Layla

Graded #101 · C

Strengths

  • Oral semaglutide dropper option plus injectable semaglutide and tirzepatide, with a brand-name upgrade path
  • Named Medical Director (Dr. Ruth Cohen) and 24-7 doctor messaging
  • Quiz-based intake with fast three to five day shipping

Where it loses points

  • Brand-inclusive GLP-1 program is expensive, starting around 1,299 dollars
  • States served are not published on the site
  • Support phone line uses a UK format, and the compounding pharmacy is not named
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard